Cited by 593Atherosclerosis and Cardiovascular DiseasesNeutrophil, Myeloperoxidase and Oxidative MechanismsNitric Oxide and Endothelin Effects

Presence of hypochlorite-modified proteins in human atherosclerotic lesions.

Open access
Hazell, L J, Arnold, L, Flowers, D, Waeg, G, Malle, E, Stocker, R·1996·Journal of Clinical Investigation

Abstract

Oxidation of LDL may contribute to atherogenesis, though the nature of the in vivo oxidant(s) remains obscure. Myeloperoxidase, the enzyme responsible for hypochlorous acid/hypochlorite (HOCl) production in vivo, is present in active form in human atherosclerotic lesions, and HOCl aggregates and transforms LDL into a high-uptake form for macrophages in vitro. Here we demonstrate HOCl-modified proteins in human lesions using an mAb raised against HOCl-modified LDL that recognizes HOCl-oxidized proteins but does not cross-react with Cu2+-, malondialdehyde-, or 4-hydroxynonenal-modified LDL. This antibody detected significantly more material in advanced atherosclerotic lesions than normal arteries, even though azide and methionine were included during sample work-up to inhibit myeloperoxidase and to scavenge HOCl. The epitope(s) recognized was predominantly cell associated and present in monocyte/macrophages, smooth muscle, and endothelial cells. The intima and cholesterol clefts stained more heavily than the center of the thickened vessels; adventitial staining was apparent in some cases. Immunostaining was also detected in a very early lesion from an accident victim, beside healthy areas that were unreactive. LDL oxidized by HOCl in vitro, but not native LDL, effectively competed with the epitopes in lesions for antibody binding. Density centrifugation of plaque homogenates and Western blot analysis showed that, in the apo B-containing lipoprotein fraction, the mAb recognized protein(s) of molecular mass greater than apo B, similar to those produced during oxidation of LDL with HOCl in vitro. Three major proteins were recognized by the anti-HOCl-modified protein antibody but not by an anti-apo B antibody in the apo B-free fraction. Together, these results demonstrate HOCl-oxidized proteins in human atherosclerotic lesions, implicating this oxidant in LDL modification in vivo.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci118576

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 39 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Adams, D.O., and T.A. Hamilton. 1992. Macrophages as destructive cells in host defense. In Inflammation: Basic principles and clinical correlates. J.I. Gallin, I.M. Goldstein, and R. Snyderman. Raven Press, New York. 637- 662.

Cited by

Sorted by citations

Authors
Hazell, L. J., Arnold, L., Flowers, D., Waeg, G., Malle, E., & Stocker, R.
Affiliations
  • The Heart Research Institute (AU)
  • The University of Sydney (AU)
  • University of Graz (AT)
Venue
Journal of Clinical Investigation
Published
1996-03-15
Volume
97
Issue
6
Pages
1535-1544
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2118480498
Cited by
592
References
39
Citations by year
2026: 3 · 2025: 4 · 2024: 14 · 2023: 14 · 2022: 19 · 2021: 12 · 2020: 18 · 2019: 20 · 2018: 26 · 2017: 16 · 2016: 12 · 2015: 17 · 2014: 15 · 2013: 13 · 2012: 16
FWCI
11.70
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Heart Foundation of Australia
  • Austrian Science Fund
  • Medical Research Council
  • National Health and Medical Research Council
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
Keywords
hypochlorite, myeloperoxidase, atherosclerosis, LDL oxidation, oxidized LDL, atherosclerotic plaque, macrophages, smooth muscle cells, endothelial cells, oxidizing agents, atherogenesis
MeSH terms
Arteriosclerosis, Humans, Hypochlorous Acid, Immunohistochemistry, Lipoproteins, LDL, Oxidation-Reduction, Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review